Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide dosing for weight loss is not one-size-fits-all—clinical trials show that individual response varies significantly based on genetics, metabolism, and baseline body composition. PlexusDx offers compounded semaglutide injections starting at $149 per month from licensed 503A pharmacies, with dosing guidance customized to your unique peptide pathways and genetic profile.

Understanding Semaglutide Starting Doses and Titration

Semaglutide therapy typically begins at a low dose to minimize gastrointestinal side effects and allow your body to adapt to the medication's appetite-suppressing mechanism. Most patients start with a 0.25 mg subcutaneous injection once weekly for the first four weeks. This introductory phase allows your GLP-1 receptors to activate gradually, reducing nausea and improving tolerability. The 0.25 mg starting dose is deliberately conservative because higher initial doses correlate with higher discontinuation rates due to digestive discomfort.

After the first month, your semaglutide dose typically increases to 0.5 mg weekly for weeks five through eight. This second-tier dose builds on the adaptation from the initial phase and begins producing more noticeable appetite reduction. Some patients experience satisfactory weight loss results at the 0.5 mg maintenance dose and may not require further increases. Your prescriber evaluates your response, side effect tolerance, and weight loss trajectory before deciding whether to advance to higher maintenance doses in subsequent months.

Standard Maintenance Doses and Weight Loss Efficacy

Most patients reach maintenance doses between 1.0 mg and 2.4 mg weekly, with the 2.4 mg dose recognized as the maximum therapeutic level in clinical practice. Clinical trial data shows that patients on 2.4 mg weekly experience an average weight loss of 15–18% of baseline body weight over 68 weeks, compared to 3% in placebo groups. However, individual response varies considerably—some patients achieve target weight loss at 1.0 or 1.5 mg, while others benefit from escalating toward the 2.4 mg maximum. Your ideal maintenance dose depends on your metabolic phenotype, genetic predispositions, and weight loss goals rather than your starting point.

The titration schedule typically advances by 0.25 mg increments every four weeks until reaching a therapeutic maintenance dose that produces desired results without intolerable side effects. This measured approach allows your body to stabilize at each dose level, helping your prescriber distinguish between true side effects and temporary adaptation responses. PlexusDx providers can use your Precision Peptide Genetic Test results to anticipate whether you may respond optimally at lower doses (due to GLP1R rs6923761 variants) or might benefit from faster titration toward higher maintenance doses.

How Genetics Influence Your Optimal Semaglutide Dose

Genetic variations in your GLP-1 receptor, GIPR pathway, and appetite-regulating genes significantly influence how your body responds to semaglutide at each dose level. The GLP1R rs6923761 variant, for example, affects receptor expression and signaling efficiency—patients with certain variants may achieve robust appetite suppression at lower doses, while others show dose-dependent response curves requiring higher maintenance levels. The Precision Peptide Genetic Test analyzes 150+ genetic insights across 14 metabolic pathways, identifying whether your peptide physiology favors rapid response or gradual titration. This personalized data allows PlexusDx providers to design semaglutide protocols that anticipate your individual dose requirements rather than following a generic escalation timeline.

Your FTO rs9939609 and MC4R rs17782313 variants further refine dosing predictions by revealing your baseline appetite-regulation capacity and metabolic efficiency. Some patients carry genetic variants that predispose them to higher appetite drive, suggesting that reaching higher semaglutide maintenance doses may be necessary for adequate hunger suppression. Others inherit variants associated with lower appetite thresholds, meaning that moderate semaglutide doses can achieve maximum weight loss benefit without unnecessary escalation. PlexusDx combines your genetic test results with your baseline metabolic metrics to establish a personalized dosing trajectory, ensuring you receive the minimum effective dose for your unique peptide pathway profile.

Dose Adjustments, Side Effect Management, and Long-Term Treatment

Approximately 15–25% of semaglutide users experience gastrointestinal side effects such as nausea, vomiting, or constipation, particularly during dose increases. If side effects become intolerable, your PlexusDx provider can pause the dose escalation, extend your timeline at the current dose, or implement adjunctive strategies such as dietary modifications or additional medications to manage nausea. In rare cases, dose reduction is warranted, though this typically results in diminished weight loss efficacy. Communicating side effect severity and duration with your provider ensures that your dosing protocol balances efficacy with tolerability—the goal is sustainable weight loss, not maximum dose administration.

Long-term semaglutide treatment requires periodic reassessment of your dose adequacy and weight loss plateau management. Most patients maintain their therapeutic dose once achieved, though some experience weight loss plateaus after 6–12 months requiring dose adjustments or protocol modifications. PlexusDx offers compounded semaglutide injections with flat monthly pricing starting at $149, meaning your dose may increase without price increases—your monthly commitment tier remains stable regardless of dose escalation. For patients interested in combination peptide therapy or genetic optimization, PlexusDx also offers the Precision Peptide Genetic Test as a $99 add-on after your first treatment month, enabling dynamic dose adjustments informed by your peptide pathway genetics.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What dose of semaglutide should I start with for weight loss?

Standard semaglutide therapy begins at 0.25 mg injected subcutaneously once weekly for four weeks, allowing your body to adapt before advancing to higher doses. PlexusDx providers may recommend this starting dose or adjust the titration timeline based on your health history and genetic predispositions identified through the optional Precision Peptide Genetic Test.

How long does it take to reach an effective semaglutide dose?

Most patients reach therapeutic maintenance doses within 8–16 weeks following standard titration protocols (0.25 mg → 0.5 mg → 1.0 mg → 1.5 mg → 2.0+ mg weekly, advancing every 4 weeks). Your individual timeline depends on tolerability and response—some patients achieve target weight loss faster, while others require gradual dose advancement to minimize side effects.

Will my PlexusDx semaglutide price increase if my dose increases?

No. PlexusDx semaglutide injections start at $149 per month flat, and your price remains stable across commitment tiers regardless of dose escalation. This means your dose may increase without financial barriers to accessing higher therapeutic levels required for your weight loss goals.

What is the maximum safe dose of semaglutide for weight loss?

The maximum studied and clinically used semaglutide dose is 2.4 mg weekly. Doses above 2.4 mg are not recommended for weight loss, though your prescriber may determine that you achieve optimal results at lower maintenance doses based on your individual response, side effect profile, and genetic factors.

How does the Precision Peptide Genetic Test help determine my semaglutide dose?

PlexusDx's $99 genetic test analyzes GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 variants—key regulators of GLP-1 receptor sensitivity and appetite pathways. These genetic insights help your provider predict whether you'll respond optimally at lower doses or may benefit from advancing toward higher maintenance levels, personalizing your entire titration timeline.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves